Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2024 Financial Results on August 8, 2024
15 Julio 2024 - 3:05PM
Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading
regenerative medicine company focused on the development,
manufacture, and commercialization of product solutions for the
Advanced Wound Care and Surgical & Sports Medicine markets,
today announced that second quarter of fiscal year 2024 financial
results will be reported after the market closes on Thursday,
August 8th.
Management will host a conference call at 5:00
p.m. Eastern Time on August 8th to discuss the results of the
quarter and provide a corporate update with a question and answer
session. Those who would like to participate may access the live
webcast here, or dial (800) 715-9871 and provide access code
6679912. The live webcast can also be accessed via the company’s
website at investors.organogenesis.com. The webcast will be
archived on the company website for approximately one year.
About Organogenesis Holdings
Inc.
Organogenesis Holdings Inc. is a leading
regenerative medicine company focused on the development,
manufacture, and commercialization of solutions for the advanced
wound care and surgical and sports medicine markets. Organogenesis
offers a comprehensive portfolio of innovative regenerative
products to address patient needs across the continuum of care. For
more information, visit www.organogenesis.com.
Investor Inquiries:
ICR Westwicke
Mike Piccinino, CFA
OrganoIR@westwicke.com
Press and Media Inquiries:
Organogenesis
communications@organo.com
Organogenesis (NASDAQ:ORGO)
Gráfica de Acción Histórica
De Jun 2024 a Jul 2024
Organogenesis (NASDAQ:ORGO)
Gráfica de Acción Histórica
De Jul 2023 a Jul 2024